ATE256656T1 - Adamantancarboximidamid-derivate und ihre anwendung als nmda-antagonisten - Google Patents

Adamantancarboximidamid-derivate und ihre anwendung als nmda-antagonisten

Info

Publication number
ATE256656T1
ATE256656T1 AT99902711T AT99902711T ATE256656T1 AT E256656 T1 ATE256656 T1 AT E256656T1 AT 99902711 T AT99902711 T AT 99902711T AT 99902711 T AT99902711 T AT 99902711T AT E256656 T1 ATE256656 T1 AT E256656T1
Authority
AT
Austria
Prior art keywords
adamantancarboximidamide
derivatives
nmda antagonists
glutamtergic
prodrugs
Prior art date
Application number
AT99902711T
Other languages
English (en)
Inventor
Nathaniel Julius Thomas Monck
Roger John Gillespie
Andrew James Bird
Original Assignee
Vernalis Res Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vernalis Res Ltd filed Critical Vernalis Res Ltd
Application granted granted Critical
Publication of ATE256656T1 publication Critical patent/ATE256656T1/de

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D333/00Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/06Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to the ring carbon atoms
    • C07D333/24Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16Anti-Parkinson drugs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C257/00Compounds containing carboxyl groups, the doubly-bound oxygen atom of a carboxyl group being replaced by a doubly-bound nitrogen atom, this nitrogen atom not being further bound to an oxygen atom, e.g. imino-ethers, amidines
    • C07C257/10Compounds containing carboxyl groups, the doubly-bound oxygen atom of a carboxyl group being replaced by a doubly-bound nitrogen atom, this nitrogen atom not being further bound to an oxygen atom, e.g. imino-ethers, amidines with replacement of the other oxygen atom of the carboxyl group by nitrogen atoms, e.g. amidines
    • C07C257/16Compounds containing carboxyl groups, the doubly-bound oxygen atom of a carboxyl group being replaced by a doubly-bound nitrogen atom, this nitrogen atom not being further bound to an oxygen atom, e.g. imino-ethers, amidines with replacement of the other oxygen atom of the carboxyl group by nitrogen atoms, e.g. amidines having carbon atoms of amidino groups bound to carbon atoms of rings other than six-membered aromatic rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2603/00Systems containing at least three condensed rings
    • C07C2603/56Ring systems containing bridged rings
    • C07C2603/58Ring systems containing bridged rings containing three rings
    • C07C2603/70Ring systems containing bridged rings containing three rings containing only six-membered rings
    • C07C2603/74Adamantanes

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Heterocyclic Compounds Containing Sulfur Atoms (AREA)
AT99902711T 1998-02-02 1999-02-01 Adamantancarboximidamid-derivate und ihre anwendung als nmda-antagonisten ATE256656T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9802225.4A GB9802225D0 (en) 1998-02-02 1998-02-02 Chemical compounds
PCT/GB1999/000321 WO1999038841A1 (en) 1998-02-02 1999-02-01 Adamantanecarboximidamide derivatives and their use as nmda antagonists

Publications (1)

Publication Number Publication Date
ATE256656T1 true ATE256656T1 (de) 2004-01-15

Family

ID=10826332

Family Applications (1)

Application Number Title Priority Date Filing Date
AT99902711T ATE256656T1 (de) 1998-02-02 1999-02-01 Adamantancarboximidamid-derivate und ihre anwendung als nmda-antagonisten

Country Status (8)

Country Link
US (1) US6262106B1 (de)
EP (1) EP1051392B1 (de)
JP (1) JP2002501942A (de)
AT (1) ATE256656T1 (de)
AU (1) AU2292199A (de)
DE (1) DE69913652D1 (de)
GB (1) GB9802225D0 (de)
WO (1) WO1999038841A1 (de)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000001376A2 (en) 1998-07-02 2000-01-13 Eisai Co., Ltd Pharmaceutical compositions and their uses for treatment of demyelinating disorders
GB9901691D0 (en) 1999-01-26 1999-03-17 Cerebrus Ltd Chemical compounds
GB0018272D0 (en) * 2000-07-25 2000-09-13 Vernalis Research Limited Chemical compounds IV
GB0202161D0 (en) * 2002-01-30 2002-03-20 Vernalis Res Ltd Chemical compounds V
TW200403066A (en) * 2002-04-30 2004-03-01 Novartis Ag New uses of substituted aminoalkanephosphonic acids
EP2260844A1 (de) * 2003-05-27 2010-12-15 Merz Pharma GmbH & Co. KGaA Kombination eines NMDA-Rezeptorantagonisten und eines selektiven Serotonin-Wiederaufnahmeinhibitoren zur Behandlung von Depression und Gemütserkrankungen
ITTO20030668A1 (it) 2003-09-02 2005-03-03 Rotta Res Lab S P A O Ra Rottapharm Derivati dell'adamantano dotati di attivita' neuroprotettiva, antidepressiva e anti-ischemica e procedimento per la loro preparazione.

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3829581A (en) 1970-07-23 1974-08-13 Du Pont Aliphatic polycyclic amidoximes as influenza antiviral agents
ES2059602T3 (es) 1989-04-14 1994-11-16 Merz & Co Gmbh & Co Uso de derivados de adamantano para la prevencion y tratamiento de isquemia cerebral.

Also Published As

Publication number Publication date
JP2002501942A (ja) 2002-01-22
EP1051392B1 (de) 2003-12-17
US6262106B1 (en) 2001-07-17
AU2292199A (en) 1999-08-16
WO1999038841A1 (en) 1999-08-05
WO1999038841A8 (en) 2000-10-12
GB9802225D0 (en) 1998-04-01
DE69913652D1 (de) 2004-01-29
EP1051392A1 (de) 2000-11-15

Similar Documents

Publication Publication Date Title
GB0018272D0 (en) Chemical compounds IV
GB9801690D0 (en) Therapeutic agents
DE69923849D1 (de) Quinolin-2-on-derivate verwendbar als antikrebsmittel
AU2002246728A1 (en) Carboline derivatives
TR200000129T2 (tr) Yepyeni spiroazabisiklik heterosiklik bileşikler.
TW200502230A (en) Dual nk1/nk3 derivatives
SE9903998D0 (sv) New compounds
ATE248824T1 (de) Substituierte phenylderivate, ihre herstellung und verwendung
MXPA05012415A (es) Inhibidores de glutamina fructosa-3-fosfato amidotransferasa (gfat).
AU2002249890A1 (en) Carboline derivatives
MXPA05010760A (es) Derivados de acido 2-(8,9-dioxo-2,6-diazabiciclo[5.2.0]non-1(7)-en-2-il)alquil fosfonico y su uso como antagonistas de receptor de n-metil-d-aspartato (nmda).
SE9903997D0 (sv) New compounds
BG104447A (en) Biphenylamidine derivatives
ATE256656T1 (de) Adamantancarboximidamid-derivate und ihre anwendung als nmda-antagonisten
MXPA05010651A (es) Compuestos de pirazol.
ATE330958T1 (de) Pyrazino 1'2':1,6öpyrido 3,4-böindolderivate
MXPA03003971A (es) Derivados de indol como inhibidores de pde5.
EP1206256B8 (de) Kombination therapie mit pentafluorobenzenesulfonamid und platin-derivate
AU2116900A (en) 2-adamantanemethanamine compounds for treating abnormalities in glutamatergic transmission
ES2185237T3 (es) 1-(asamantil)amidinas y su utilizacion en el tratamiento de estados generalmente asociados con anomalias en la transmision glutamatergica.
DE60027204D1 (en) Benzamidinderivate
ES2159489A1 (es) Nuevos derivados de imidazol con actividad antiinflamatoria.
AU2406700A (en) 3,4-dihydro-2h-benzo(1,4)oxazinyl-methyl(3-(1h-indol-3-yl)-a kyl)-amines
AU2178199A (en) Azetidinecarboxamide derivatives for the treatment of cns disorders
AU2178099A (en) Azetidinecarboxamide derivatives for treating cns disorders

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties